Curr Stem Cell Res Ther
. 2023;18(1):35-53.
doi: 10.2174/1574888X17666220426115831
Review Article
Author(s): Vahid Kia, Reza Eshaghi-Gorji, Reyhaneh Nassiri Mansour, Hadi Hassannia, Elham Hasanzadeh, Mobina Gheibi, Amir Mellati
and Seyed Ehsan Enderami*
In December 2019, a betacoronavirus was isolated from pneumonia cases in China and rapidly turned into a pandemic of COVID-19. The virus is an enveloped positive-sense ssRNA and causes a severe respiratory syndrome along with a cytokine storm, which is the main cause of most complications. Therefore, treatments that can effectively control the inflammatory reactions are necessary. Mesenchymal Stromal Cells and their EVs are well-known for their immunomodulatory effects, inflammation reduction, and regenerative potentials. These effects are exerted through paracrine secretion of various factors. Their EVs also transport various molecules such as microRNAs to other cells and affect recipient cells' behavior. Scores of research and clinical trials have indicated the therapeutic potential of EVs in various diseases. EVs also seem to be a promising approach for severe COVID-19 treatment. EVs have also been used to develop vaccines since EVs are biocompatible nanoparticles that can be easily isolated and engineered. In this review, we have focused on the use of Mesenchymal Stromal Cells and their EVs for the treatment of COVID-19, their therapeutic capabilities, and vaccine development.
Keywords: Betacoronavirus, mesenchymal stromal cells, COVID-19, nanoparticles, SARS-CoV-2, therapeutic capabilities